06:30 AM EST, 12/27/2024 (MT Newswires) -- BeiGene ( BGNE ) said Friday that its antibody drug Tevimbra has received approval from the US Food and Drug Administration for first-line treatment of stomach-esophagus junction cancer.

The approved indication covers a certain type of unresectable or metastatic gastroesophageal junction adenocarcinoma, a rare cancer at the area where the esophagus connects with the stomach, BeiGene ( BGNE ) said.